- Home
- VRNA
VRNA
Verona Pharma plc
as 05-20-2024 11:33am EST
$.
-
$.
-.%
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
| Founded: | 2005 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 1.1B | IPO Year: | 2017 |
| Target Price: | $33.60 | AVG Volume (30 days): | 456.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.83 - $23.07 | Next Earning Date: | 05-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 374.48% |
Share on Social Networks:
Stock Insider Trading Activity of Verona Pharma plc (VRNA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rickard Kathleen A. | VRNA | Chief Medical Officer | May 1 '24 | Sell | $1.96 | 36,248 | $71,031.58 | 2,621,552 | SEC Form 4 |
| Rickard Kathleen A. | VRNA | Chief Medical Officer | Feb 1 '24 | Sell | $2.22 | 36,248 | $80,503.18 | 2,731,624 | SEC Form 4 |
| Edwards Martin | VRNA | Director | Nov 20 '23 | Buy | $1.84 | 33,736 | $61,973.03 | 144,800 | SEC Form 4 |
Latest Verona Pharma plc News
VRNA Breaking Stock News: Dive into VRNA Ticker-Specific Updates for Smart Investing
GuruFocus.com
10 days ago
Verona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic Overview
Insider Monkey
10 days ago
Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript
MT Newswires
11 days ago
Verona Pharma Signs Financing Agreements for Up to $650 Million
MT Newswires
11 days ago
Verona Pharma Shares Decline After Q1 Loss Widens
GlobeNewswire
11 days ago
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
11 days ago
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
GlobeNewswire
18 days ago
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
GlobeNewswire
25 days ago